MLR Review Software: How Do You Pull an Expired Claim Out of the Field Before an Inspector Does?

Why promotional review breaks a commercial operation

It is 6:40pm on a Tuesday and a congress opens Thursday. The brand team needs one rep-triggered email and one booth panel approved. The medical reviewer signed off this morning on a version legal has since edited. Regulatory sits in another time zone and opens the queue at 8am local, which is after the print deadline. The asset itself is a file inside a review tool, but the real argument is happening in an Outlook thread with a marked up copy attached called panel_v6_MLR_comments_FINAL2.pdf. Nobody in that thread can say with certainty which reference supports the third bullet.

The stack around this is usually Veeva Vault PromoMats or Vodori Pepper Flow for review, a reference library somewhere else, agency creative in InDesign or Figma, distribution to rep tablets through a CRM (Customer Relationship Management), a product website owned by a separate team, and Form FDA 2253 packets assembled by hand at first use. Each tool does its job. None of them owns the object that actually carries the liability. That object is not the asset and not the file. It is the claim: a specific statement about the product, tied to a specific reference, approved for a specific indication, in a specific market, for a specific period.

Because nothing owns the claim, the same sentence ends up in forty assets in forty slightly different wordings. When the underlying reference is superseded by a label change or a newer publication, nobody can produce the list of live assets that now need to come down. Building that list by hand over a weekend is what your compliance team already does, and it is exactly what an inspector asks for. The gap between that list and the material still on a rep tablet is the exposure.

Problem 1: the system reviews assets, but the risk lives in claims

Vault PromoMats and Pepper Flow are document-centric by design. You upload an asset, reviewers annotate it, it earns an approval and an expiry date, and it ships. For a single brand in a single market that model is honest and sufficient. What it does not give you is a register in which the claim itself is the record, with its own version history, its own approved wording, its own linked substantiation and its own status per indication and per market.

The cost of that shows up on your second brand. A claim is approved in the core deck. An agency rewrites it slightly for a banner. A field team paraphrases it into an email template. Three variants now exist, all technically approved, none identical, and only one traces cleanly to the substantiation the medical reviewer actually read. Aprimo comes from marketing resource management and is stronger on planning than on claim-level substantiation. Ennov is document-centric in the same way Vault is. None of them makes the claim the unit of record, so the drift is invisible until someone goes looking.

A custom build inverts the model. The claim becomes the primary entity: versioned, with references attached at claim level, with a status per market and per indication. An asset is then a composition of placements, each bound to a specific claim version. Approving an asset means approving the placements, and the reviewer opens a file where eight of ten placements are already-approved claim versions and only two need fresh reading. That is why the second and third brand stop multiplying your review load linearly, and it is usually the argument that gets the build funded.

Problem 2: annotation stops working the moment the asset is not a page

Reviewing a printed leave-behind is a solved problem. Reviewing a ninety second product video, an interactive detail aid with eleven branching screens, a banner set with rotating frames, or a congress booth with a touchscreen is not. Reviewers need to comment on a timecode, on a specific state of an interactive module, on frame three of a rotation. What actually happens is that someone exports screenshots into a slide deck and reviewers comment on the deck, which means the approved record is a set of stills and not the thing that shipped.

This is a fair and specific gap in the packaged tools. Vault PromoMats handles video annotation, but branching interactive content and HTML modules still tend to be reviewed as flattened exports. Pepper Flow is lighter and faster for standard assets but thinner here. Approve a still instead of the running module and your approval does not cover what the field is showing.

A custom build treats the interactive asset as first class. Annotation anchors to a timecode for video and to a named state for an interactive module, so the comment thread survives a re-cut. The approved record stores the built artifact with a hash, not a screenshot, and the field distribution package is generated from that exact artifact. When a reviewer asks what changed between version four and version five, the system replays the two states side by side rather than asking a project manager to remember.

Problem 3: withdrawal is a manual sweep and it is always late

Expiry is where the money and the exposure sit. A reference is superseded, a label changes, an indication is narrowed, a study is retracted. Every asset containing every claim resting on that reference is now a liability, and those assets are scattered across a CRM library on rep tablets, a public website, a congress portal, an email platform, printed inventory in a warehouse, and a shared drive nobody admits to.

Packaged review tools set an expiry date on the asset and notify an owner. That is not the same thing as withdrawal. Expiry by date does not fire when a reference changes mid-cycle, and notification is not removal. The gap between an asset going invalid and it actually disappearing from a tablet is where enforcement exposure lives, and it is the part every one of these tools leaves to a human with a spreadsheet.

A custom build wires the cascade directly. A reference status change propagates to every claim version resting on it, then to every asset placement binding that claim, then to a withdrawal job per distribution endpoint: a CRM library sync that unpublishes, a website API call, an email platform template disable, a printed inventory flag with a physical destruction task and a signature. The output is one screen showing what is invalid, where it still exists and who is accountable, with a timestamped completion record. That turns a weekend reconstruction into a ten minute answer.

Problem 4: agencies and affiliates get priced off the system

Seat pricing on packaged MLR platforms is real money, so companies buy seats for reviewers and brand leads and stop there. The people actually producing the material, meaning creative agencies, medical writers, congress vendors and local affiliate marketers, end up outside the system. They work in email. Comments arrive as marked up files. Version control returns to filenames.

The affiliate problem compounds this. A local market review chain is not the US chain with different names. It has different reviewer roles, different local codes of practice, different mandatory disclosure text, sometimes a national association pre-vetting step, and a different definition of what even counts as promotional. Configuring that in a packaged tool is a project each time, so affiliates quietly run parallel processes in local files.

A custom build removes the seat as the barrier. External contributors get scoped, time limited access to the specific assets they work on, with no licence economics forcing them out. Review chains are defined as rules rather than as one global template: routing by market, by asset type, by whether a claim version is already approved locally, with parallel review where the roles do not depend on each other and serial review where they do. The measurable win is that the review clock starts when the agency uploads rather than when someone opens an attachment.

What this costs and how long it takes

Across the projects Digital Heroes has delivered, the honest shape here is a focused first release at $90,000 to $180,000 shipping in 14 to 20 weeks, covering the claims register with reference linking, asset composition, routed review with annotation, and audit trail. A full platform adding video and interactive state annotation, market and affiliate chains, expiry-driven withdrawal to live endpoints, 2253 packet assembly and a reporting layer runs $250,000 to $600,000 phased over 8 to 14 months.

What pushes the number up in this category specifically:

• Number of markets, because each affiliate chain is a distinct rule set and a distinct set of mandatory local text
• Distribution endpoints for withdrawal, since a CRM library, a CMS, an email platform and printed inventory are four separate integrations with four separate failure modes
• Migration of an existing approved library, because bringing legacy assets across without re-reviewing them means reconstructing claim bindings after the fact
• Interactive and video annotation, which is genuinely harder engineering than page annotation
• Validation expectations, if your quality organisation treats the system as GxP relevant and wants qualification documentation

What keeps it down: starting with one brand, one market and the core claim set. Companies that migrate every brand at once spend months in data cleanup and lose the momentum that funds phase two.

Build versus buy, and when buying is the right call

Buy if you are a single brand company in one market with a small asset volume and a review committee that fits around one table. Vault PromoMats is the market default for a reason and Pepper Flow is a genuinely lighter, faster option at smaller scale. A custom build at that size is a distraction from launch.

Build when two or more of these hold. Your claim library is larger than your asset library in practical terms, meaning the same statements recur across brands and channels. You operate in more than three markets with genuinely different review chains. Your assets are majority interactive or video rather than page based. Your last reference change triggered a manual sweep that took more than a day. Your agencies and affiliates are outside the system because of seat cost.

The underlying test is whether promotional review is an approval queue or a claims governance function at your company. If it is a queue, buy the queue. If your commercial risk is really about which statements are live where, and no packaged tool models statements, then you are paying people to be the missing data model, and that is what a build replaces.

How to choose a developer for MLR review software

Ask them to model the data before they quote. A developer who has done this draws claim, claim version, reference, indication, market status, asset, placement and distribution endpoint, and can explain why the placement is the join that makes withdrawal possible. A developer who draws documents and approvals has built a document management system and will hand you a slower Vault.

Ask specifically how withdrawal reaches a rep tablet. If the answer is a notification email to the asset owner, they have not solved the problem you are buying. You want to hear about endpoint adapters, retry behaviour, and a completion record per endpoint.

Ask what they will do about video and interactive annotation, and make them show you rather than describe it. Anchoring a comment to a timecode and to a module state is where this category is actually difficult, and it is where most quotes are quietly assuming flattened screenshots.

Ask what they will produce for audit trail integrity and controlled access. A record no one can quietly edit is the minimum here, and a good developer raises it before you do.

Ask who owns the code and get it in writing before kickoff. You should own the repository, the cloud accounts and the right to hire anyone else to continue the work. At Digital Heroes the code is yours from the first commit, and we would tell you to walk away from anyone who hedges on that.